Search
Jefferies London: Jefferies Chairman of Global Healthcare Philip Ross discusses the environment for biotech and deals
He shares his take on the capacity for pharma to do more buying, and list his favorite areas of science, which include I&I, CNS/Neurology, and modalities such as bi-specifics and tri-specifics. Coverage brought to you by
5 hours ago
Off-Target Effects Episode 4: Matt speaks with Philip Ross, one of the most experienced and successful bankers in healthcare, about the M&A landscape and his decision to join Jefferies last year
Philip Ross talks about the outlook for M&A in our industry, and describes the pharma revenue growth demands that will be driving it. He...
Jun 30
Discussing hot button issues for biotech, and how they do or don't affect the mechanics of M&A, with one of the most experienced bankers in healthcare, Jefferies' Philip Ross
He describes how some front and center issues for biotech either do or don't affect the M&A environment such as China, negative enterprise values, the FTC, valuations, the patent cliff, and more.
Jun 27
.png){kind=logo}
